Biodegradable magnesium alloy implantable medical devices are protected to delay onset of corrosion, and thus biodegradability, or to corrode more uniformly. The protection allows for extended effective use of the devices while maintaining biodegradability. Examples of protective coatings include conversion coatings that at least partially remove exposed second phases from a surface of the magnesium alloy and coatings that provide a barrier between water and the surface of the magnesium alloy.

The present invention relates to a biodegradable alloy of Formula (I): Mg—Zn—X, wherein X represents —Ca—Mn or —Dy—Sr, wherein Zn is about 0.1 wt % to about 3.0 wt %, Dy is about 0.1 wt % to about 0.7 wt %, Sr is about 0.1 wt % to about 0.9 wt %, Ca is about 0.1 wt % to about 1.5 wt %, Mn is about 0.1 wt % to about 0.9 wt % and Mg is balance with impurities. The present invention further relates to a method for producing alloys, wherein the method comprises: (a) placing alloy components in a crucible, wherein the alloy components are placed in the crucible in a multilayer arrangement; (b) melting the alloy components at about 700° C. to about 850° C.; (c) stirring the melt of step (b) at about 400 rpm to about 500 rpm; (d) atomizing the melt of step (c) into millimeter size droplets using jets of inert gas; and (e) cooling and depositing the atomized alloy melt to obtain an ingot.

Biodegradable magnesium alloy implantable medical devices are protected to delay onset of corrosion, and thus biodegradability, or to corrode more uniformly. The protection allows for extended effective use of the devices while maintaining biodegradability. Examples of protective coatings include conversion coatings that at least partially remove exposed second phases from a surface of the magnesium alloy and coatings that provide a barrier between water and the surface of the magnesium alloy.

The present invention provides for nanostructured fibrin and agarose hydrogels, preferably type VII agarose hydrogels, (NFAH) or non-nanostructured or pre-nanostructured fibrin and agarose hydrogels, preferably type VII agarose hydrogels, (FAH), as hemostatic agents designed for use as an adjunct or primary treatment in moderate intraoperative hemorrhage and in trauma. These hydrogels can be applied topically to the wound either on the skin in a laparotomy or as non-invasive manner in surgical procedures. Its nanostructure technology generates an adhesive stable fibrin clot required for hemostasis. The attachment properties of the hydrogel, as well as the rapid formation of a fibrin clot, ensures that a strong stable fibrin clot is formed shortly after application.

A biocompatible membrane comprised of alginate and hyaluronate. The membrane may be used to prevent unwanted scarring after surgery. The tissue adherence and the rate of bioresorption of the membrane may be modified through an external stimulus comprising a sequestering agent and a viscosity modifier.

An intraluminal endoprosthesis has a biodegradable metallic supporting structure and a biodegradable sleeve surrounding the supporting structure. The sleeve includes fibres applied to the outer side of the supporting structure. The sleeve can be formed from fibres that each have a polymer core and a hydrogel casing. The sleeve can the sleeve be formed from a fibre mixture of polymer fibres and hydrogel fibres.

The disclosure pertains to implantable medical devices for controlled delivery of therapeutic agents. Some devices according to the disclosure have a titanium reservoir, and a porous titanium oxide based membrane to control the rate of release of the therapeutic agent. The reservoir contains a formulation of the active agent, including a stabilizer for the active agent, wherein the stabilizer is provided in an extended-release configuration or a sustained release carrier.

The purpose of the present invention is to provide an injectable sol into a body, suited for delivery through a catheter, and usable for tissue perforation closure, ulcer protection, or vascular embolization. Provided are a sol for tissue perforation closure, a sol for ulcer protection, and a sol for vascular embolization, each containing from 0.6 mass % to 3 mass % of a collagen, water, from 200 mM to 330 mM sodium chloride, and a buffer and having a pH from 6.0 to 9.0.

The invention relates to self-assembled organosilane- and small molecule drug-containing coatings for resorbable medical implant devices. The coatings can be prepared from precursor compositions containing an organosilane and a small molecule drug, and can be applied to substrates. Prior to applying the coatings, the surfaces of the substrates can be pretreated. The coatings can be functionalized with a binding compound that is coupled with an active component. The coatings can be applied using various techniques and apparatus, more particularly, by a deep-coating process conducted at ambient conditions.

The invention provides compositions featuring chitosan and methods for using such compositions for the local delivery of biologically active agents to an open fracture, complex wound or other site of infection. Advantageously, the degradation and drug elution profiles of the chitosan compositions can be tailored to the needs of particular patients at the point of care (e.g., in a surgical suite, clinic, physician's office, or other clinical setting).